aTYR PHARMA INC (LIFE) Nonoperating Income (Expense) USD 2018 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
aTYR PHARMA INC quarterly/annual Nonoperating Income (Expense) history and growth rate from 2018 to 2024.
  • aTYR PHARMA INC Nonoperating Income (Expense) for the quarter ending March 31, 2024 was $1.15 M, a 37.6% increase year-over-year.
  • aTYR PHARMA INC Nonoperating Income (Expense) for the twelve months ending March 31, 2024 was $4.84 M, a 189% increase year-over-year.
  • aTYR PHARMA INC annual Nonoperating Income (Expense) for 2023 was $4.52 M, a 326% increase from 2022.
  • aTYR PHARMA INC annual Nonoperating Income (Expense) for 2022 was $1.06 M, a 346% increase from 2021.
  • aTYR PHARMA INC annual Nonoperating Income (Expense) for 2021 was $238 K.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $4.84 M $1.15 M +$314 K +37.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 $4.52 M $1.2 M +$771 K +181% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-14
Q3 2023 $3.75 M $1.27 M +$1.03 M +415% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $2.73 M $1.22 M +$1.05 M +646% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-09
Q1 2023 $1.67 M $835 K +$611 K +273% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 $1.06 M $427 K +$348 K +441% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 $713 K $247 K +$188 K +319% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $525 K $163 K +$110 K +208% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $415 K $224 K +$177 K +377% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $238 K $79 K +$74 K +1480% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-14
Q3 2021 $164 K $59 K +$147 K Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $17 K $53 K +$182 K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 -$165 K $47 K +$154 K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 -$319 K $5 K +$176 K Oct 1, 2020 Dec 31, 2020 10-K 2023-03-14
Q3 2020 -$495 K -$88 K +$59 K +40.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$554 K -$129 K +$78 K +37.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-11
Q1 2020 -$632 K -$107 K +$153 K +58.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14
Q4 2019 -$785 K -$171 K +$188 K +52.4% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-15
Q3 2019 -$973 K -$147 K +$290 K +66.4% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-13
Q2 2019 -$1.26 M -$207 K +$245 K +54.2% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 -$1.51 M -$260 K +$187 K +41.8% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
Q4 2018 -$1.7 M -$359 K Oct 1, 2018 Dec 31, 2018 10-K 2021-03-24
Q3 2018 -$437 K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$452 K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
Q1 2018 -$447 K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.